title: [Clinical curative efficacy of inducing remission for the newly diagnosed aged AML patients by chemotherapy with IA and DA regimens].
abstract: This study was aimed to explore the clinical efficacy and toxicity of idarubicin (IA regimen) and daunoru-bicin combined with cytarabine (DA regimen) for treating aged patients with AML as induction chemotherapy. The clinical data of 60 newly diagnosed AML aged patients treated with IA or DA regimen were analyzed retrospectively. IA regimen group included 22 patients (8 male and 14 females with median age of 66 yrs), while the DA regimen group included 38 patients (20 males and 18 females with median age of 64 yrs). The complete remission rate, total effective rate and adverse effects after one chemotherapy course were compared. The results showed that the CR rate in IA regimen group was 63.63%, which was significantly higer than that in DA regimen group (31.58%) (P < 0.05). The total effective rate was 63.63% and 36.84% respectively in IA and DA regimen groups, there was significant difference between the two groups (P < 0.05). Both the hematological and non-hematological adverse effects were observed and no difference was found in the two regimen groups, neither in myelosupression (P > 0.05), the major hematological adverse effects, nor in non-hematological adverse effects (P > 0.05). It is concluded that for aged AML patients, IA regimen can achieve a higher CR rate and higher total effective rate than that in DA regimen without increase of adverse effects after one induction chemotherapy course.
authors.affiliation: Zhengzhou Central Hospital Affilated to Zhengzou Universty, Zhengzhou 450007, Henan Province, China.
authors.forename: Dong-Hua
authors.initials: DH
authors.lastname: Tian
authors.affiliation: Department of Hematology, The First Hospital Affiliated to Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Si-Lin
authors.initials: SL
authors.lastname: Gan
authors.affiliation: Department of Hematology, The First Hospital Affiliated to Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Hai-Zhou
authors.initials: HZ
authors.lastname: Xing
authors.affiliation: Department of Hematology, The First Hospital Affiliated to Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Yan-Fang
authors.initials: YF
authors.lastname: Liu
authors.affiliation: Department of Hematology, The First Hospital Affiliated to Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors.forename: Xin-Sheng
authors.initials: XS
authors.lastname: Xie
authors.affiliation: Department of Hematology, The First Hospital Affiliated to Zhengzhou University, Zhengzhou 450052, Henan Province, China. E-mail:sunhui371@medmail.com.cn.
authors.forename: Hui
authors.initials: H
authors.lastname: Sun
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D060828:Induction Chemotherapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D003561:Cytarabine; D015255:Idarubicin